MIRM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Raises Full-Year Sales Guidance

Nov 3, 2026

8-K

Mirum Announces Positive Results from PROGRESS Study Cohort 2 of ATEBRIOZ in Pediatric FOP Patients

Oct 26, 2026

8-K

Mirum Pharmaceuticals Announces Positive Topline Results from Phase 3 EXPAND Study of LIVMARLI (maralixibat)

Oct 13, 2026

8-K

Mirum Pharmaceuticals Announces FDA Approval of Atebrioz and Positive Phase 3 AZURE-1 Results for Brelovitug

Sep 28, 2026

8-K

Mirum Pharmaceuticals Appoints Rob Myers as Chief Medical Officer and Announces Departure of Joanne Quan

Sep 8, 2026

8-K

Mirum Pharmaceuticals Reports Q2 2026 Financial Results and Increases Full-Year Sales Guidance

Aug 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

ATM | Offering amount: $200,000,000

Nov 2, 2023

424B5

SHELF OFFERING | Shares amount: 3,478,261 | Share price: $23.00 | Offering amount: $80,000,003.00 | Bank: J.P. Morgan, SVB Securities, Evercore ISI, Raymond James

Aug 10, 2022

424B5

Shares amount: 2,821,869 | Offering amount: $80,000,000.00 | Bank: J.P. Morgan, SVB Securities, Evercore ISI, Raymond James

Aug 9, 2022

424B5

Common Stock-

Dec 15, 2020

424B5

Common Stock-

Dec 14, 2020

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Jan 9, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Feb 25, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2026

Form D - Notice of Exempt Offering of Securities - Item 06c

Jan 29, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 9, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Aug 12, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 14, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Peetz Christopher (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

Howe Jolanda (Reporting)

Oct 19, 2026

Myers Robert Paul (Reporting)

Oct 14, 2026

Peetz Christopher (Reporting)

Oct 6, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 10, 2022

CORRESP

Form CORRESP - Correspondence

Jun 6, 2022

LETTER

Form UPLOAD - SEC-generated letter

Jun 3, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 13, 2020

LETTER

Form UPLOAD - SEC-generated letter

Aug 7, 2020

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 9, 2020

Mirum Pharmaceuticals, Inc. MIRM · SEC Filings